Specifically, EGF-labeled liposomes have been used to direct eco-AgNPs to EGFR-overexpressing cells [63], while various nanotherapeutics have been conjugated with antibodies like Trastuzumab to target HER2-positive breast cancers [36, 64]. This evidence concerns the gene ERBB2 and breast cancer.